The U.S. Food and Drug Administration has approved Lantheus Holdings’ TAUKLARIFY™ (florquinitau F 18 injection), adding a new molecular imaging option for identifying tau pathology in adults with cognitive impairment who are being evaluated for Alzheimer’s disease.
Lantheus announced the approval on August 14, 2026. TAUKLARIFY, also known during development as MK-6240, is an F18-labeled radiodiagnostic agent used with positron emission tomography, or PET, to identify patients with tau neurofibrillary tangle pathology associated with Alzheimer’s disease. Its safety and effectiveness have not been established for assessing tauopathies unrelated to Alzheimer’s disease.
The approval expands the role of molecular imaging in a field that is increasingly moving beyond symptom-based assessment toward the direct measurement of biological markers associated with neurodegenerative disease.
Alzheimer’s disease is characterized by several pathological processes, particularly the accumulation of amyloid-beta plaques and abnormal tau proteins in the brain. While amyloid imaging has already become an important part of the Alzheimer’s diagnostic and treatment landscape, tau provides a different layer of information.
Tau pathology tends to accumulate as the disease progresses and its distribution is closely associated with neurodegeneration and cognitive impairment. PET imaging capable of visualizing tau therefore has potential value in helping clinicians better characterize the biological stage of Alzheimer’s disease.
TAUKLARIFY does not independently diagnose Alzheimer’s disease. Instead, it provides imaging information that should be interpreted together with clinical assessment and other diagnostic tools.
Lantheus specifically warns that a negative TAUKLARIFY scan does not necessarily exclude tau neurofibrillary tangle pathology, while a positive scan does not by itself confirm the presence of Alzheimer’s disease-related pathology. Additional evaluation should be considered when uncertainty remains.
The FDA approval was supported by two blinded image-reading studies using scans from more than 500 participants across three clinical trials. Those trials included cognitively unimpaired participants, patients with mild cognitive impairment and people with mild Alzheimer’s disease dementia, providing data across different stages of cognitive function.
Independent readers who were blinded to participants’ clinical information and amyloid-beta PET results classified the TAUKLARIFY scans as positive or negative for tau neurofibrillary tangle pathology.
In the first study, which evaluated images from 279 subjects, positive percent agreement across readers ranged from 80% to 88%, while negative percent agreement ranged from 98% to 99%. In a second study involving 338 subjects, positive percent agreement ranged from 68% to 82%, with negative percent agreement of 93% to 99%. Inter-reader agreement was high in both studies.
Safety was evaluated in 1,734 people. The most commonly reported adverse reactions were relatively infrequent and included headache, nausea, injection-site reactions, dizziness and abdominal discomfort.
For the pharmaceutical industry, however, the significance of the approval extends beyond another diagnostic imaging product.
The Alzheimer’s market is changing rapidly as therapies designed to modify underlying disease biology increase demand for more precise patient assessment.
Amyloid biomarkers currently play a central role in identifying patients for several treatment approaches, but tau imaging could increasingly complement amyloid PET, blood-based biomarkers and cerebrospinal-fluid testing by providing additional information about disease pathology.
The emergence of disease-modifying Alzheimer’s therapies is effectively creating a parallel market for more sophisticated diagnostic technologies.
That dynamic gives radiopharmaceutical companies such as Lantheus an increasingly important role within the Alzheimer’s treatment ecosystem.
Lantheus said it intends to continue using TAUKLARIFY through its Pharma Solutions business to support therapeutic development programs while assessing the appropriate pathway toward broader commercial availability.
This distinction is important. FDA approval does not necessarily mean that TAUKLARIFY will immediately become broadly available at every PET imaging center.
Radiopharmaceutical commercialization requires specialized manufacturing, radioactive isotope distribution, imaging infrastructure and trained readers. F18-based agents also have time-sensitive logistics because of radioactive decay.
The approval nevertheless gives Lantheus another potentially valuable asset in neurological imaging.
It comes at a particularly important moment for the company. Earlier in August, Curium announced a definitive agreement to combine with Lantheus, further highlighting consolidation and strategic interest in radiopharmaceutical diagnostics and therapeutics. Lantheus’ own investor-relations materials list that agreement on August 3, followed by the TAUKLARIFY approval less than two weeks later.
From a clinical-development perspective, tau PET could also play an expanding role in pharmaceutical trials.
Drug developers increasingly need biomarkers that can help select trial participants, measure biological disease characteristics and determine whether experimental therapies are affecting underlying pathology.
Tau imaging may therefore have value not only as a commercial diagnostic tool but also as an enabling technology for the next generation of Alzheimer’s clinical programs.
That is particularly relevant as the industry begins looking beyond amyloid alone.
Alzheimer’s disease is biologically complex, and a patient’s amyloid status does not fully describe the severity or distribution of neurodegeneration. Combining multiple biomarkers could eventually allow more precise patient stratification and treatment decisions.
TAUKLARIFY’s approval reflects a broader shift in Alzheimer’s medicine: diagnosis is becoming increasingly molecular, quantitative and integrated with drug development.
The immediate commercial impact will depend on Lantheus’ launch strategy, reimbursement, access to PET infrastructure and the extent to which neurologists incorporate tau imaging into clinical practice.
But strategically, the approval gives the U.S. Alzheimer’s market another FDA-cleared tool for assessing one of the disease’s defining pathological markers.
As Alzheimer’s treatment becomes more targeted, technologies capable of showing what is happening inside the brain are likely to become increasingly valuable alongside the therapies themselves.
